Literature DB >> 1884728

Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients.

U Schuler1, P Waidelich, H Kolb, T Wagner, G Ehninger.   

Abstract

High-dose cyclophosphamide is used immediately after total body irradiation (TBI) in conditioning for bone marrow transplantation (BMT). Possible interactions of the two treatment modalities were sought by measuring the blood pharmacokinetics of CP and 4-hydroxy-cyclophosphamide (4-HOCP) in patients undergoing BMT. There was a non-significant trend to a shorter half-life of CP compared to reported values. Exposure to 4-HOCP, the major metabolite of CP, did not appear to be altered by prior TBI of the patient.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1884728     DOI： 10.1007/bf00315233

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  22 in total

1.  Fluorometric determination of acrolein and related compounds with m-aminophenol.

Authors:  R A Alarcon
Journal:  Anal Chem       Date:  1968-09       Impact factor: 6.986

2.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Reconstitution studies on the involvement of radiation-induced lipid peroxidation in damage to membrane enzymes.

Authors:  O Yukawa; S Nagatsuka; T Nakazawa
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1983-04

4.  Effects of total body irradiation followed by bone marrow transplantation on the disposition kinetics of mitomycin-C in the rat.

Authors:  R G Buice; B C Veit; S E McAlpin; B J Gurley; P Sidhu
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-06

5.  Modification of pharmacological activity following x-irradiation.

Authors:  V Nair
Journal:  Radiat Res       Date:  1967-02       Impact factor: 2.841

6.  Inhibition by radiation of the development of drug-detoxification enzymes.

Authors:  K P DuBois
Journal:  Radiat Res       Date:  1967-02       Impact factor: 2.841

7.  PLasma half-life and urinary excretion of cyclophosphamide in children.

Authors:  N E Sladek; J Priest; D Doeden; C J Mirocha; S Pathre; W Krivit
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

8.  Studies of microsomal glucose-6-phosphatase on liver of irradiated rats.

Authors:  P Bernard; Y Neveux; G Rocquet; J Drouet
Journal:  Enzyme       Date:  1980

9.  Radiation-induced lipid peroxidation and membrane-bound enzymes in liver microsomes.

Authors:  O Yukawa; T Nakazawa
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1980-06

10.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
View more
  3 in total

1.  Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.

Authors:  D Zhou; Y Lu; M S Steiner; J T Dalton
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

Review 3.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.